Labetalol Should Be Continued During Follistim Treatment for Ovulation Induction
Continue labetalol without interruption when starting Follistim (follitropin alfa) for ovulation induction in hypertensive women, as there is no contraindication to concurrent use and maintaining blood pressure control is critical for maternal and fetal outcomes. 1
Rationale for Continuing Labetalol
Labetalol is a first-line antihypertensive agent during pregnancy and reproductive treatment, with established safety data 1. The 2025 Circulation guidelines explicitly endorse labetalol (alongside extended-release nifedipine) as preferred therapy for hypertension in women of reproductive capability 1. Key considerations include:
- No teratogenicity: Unlike ACE inhibitors or ARBs which are absolutely contraindicated, labetalol has no reported teratogenic effects 1
- Minimal fetal risks: While potential concerns exist for fetal growth restriction, bradycardia, and hypoglycemia, these risks are minimal in clinical practice 1
- Proven efficacy: Labetalol effectively reduces blood pressure without major metabolic disturbances during pregnancy 2
No Drug Interaction Between Labetalol and Follistim
The FDA labeling for Follistim makes no mention of contraindications or interactions with antihypertensive medications 3. Follistim is administered subcutaneously for ovarian stimulation with dosing based on ovarian response, not affected by concurrent medications. The two drugs work through completely independent mechanisms:
- Follistim: Recombinant FSH stimulating follicular development
- Labetalol: Combined alpha/beta-adrenergic blocker for blood pressure control
Practical Management Algorithm
During Follistim Treatment:
- Continue current labetalol dose without modification at treatment initiation
- Monitor blood pressure closely during ovarian stimulation, as hormonal changes may affect BP
- Adjust labetalol dosing to TID or QID if needed, as pregnancy-related accelerated drug metabolism may require more frequent dosing 1
- Target blood pressure: Maintain BP <140/90 mmHg, with recent guidelines favoring normalization even in non-severe hypertension 4
Key Monitoring Points:
- Blood pressure should be checked at each Follistim monitoring visit (typically every 2-3 days during stimulation)
- Watch for signs of ovarian hyperstimulation syndrome (OHSS), which can be exacerbated by uncontrolled hypertension
- The only contraindication to labetalol is reactive airway disease 1
Important Caveats
Do not discontinue labetalol based on concerns about fertility treatment. Uncontrolled hypertension poses far greater risks to both conception success and maternal health than the minimal risks associated with labetalol use. The 2022 international guidelines review confirms that oral labetalol is now the most frequently endorsed first-line agent for hypertension in pregnancy and reproductive contexts 4.
If blood pressure becomes difficult to control during stimulation, nifedipine (extended-release) can be added as combination therapy rather than switching medications 1. This approach maintains the proven safety profile while optimizing BP control during the critical ovulation induction period.